Navigation Links
OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
Date:7/23/2012

SAN DIEGO, July 23, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck (SCCHN). The data are being presented July 22-24 at the 8th International Conference on Head and Neck Cancer in Toronto, Canada. A link to the abstract can be found here: http://ahns.jnabstracts.com/Detail.aspx?ID=0778

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

In these studies, electrochemotherapy was compared against surgery for quality of life, safety, survival and local control at eight months, where local control is defined as destruction of the treated tumor without evidence of reappearance of the tumor at the treatment site. The data show OMS ElectroChemotherapy achieved the primary endpoint of preserving quality of life compared to surgery, and appears to be safe and comparable to surgery in achieving control in locally recurrent or second primary SCCHN. This therapy represents a viable alternative to potentially major surgical interventions for this patient population, where recurrent tumors in SCCHN usually have a poor prognosis with a local control rate of 40-50 percent and frequently associated loss of organ function.

Paul Goldfarb, M.D., Consulting Medical Director of OncoSec overseeing the Phase III studies, said, "Despite the early termination of this study, delayed interim analysis of these data clearly demonstrated there was equivalence in safety, local control at eight months and survival between electrochemotherapy and surge
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
6. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
7. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
10. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... YORK, Dec. 20, 2010 Health organizations will undergo ... new rules and payment models, continuing cost pressures and ... Industry Issues of 2011 , published today by PwC,s ... of 1,000 U.S. adults, PwC found that consumers don,t ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... 8:30 a.m. Eastern Time on Monday, December 20, to discuss ... in central retinal vein occlusion (CRVO) and the week 52 ... patients with diabetic macular edema (DME).  A press release will ...
Cached Medicine Technology:Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 2Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 3Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 4Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 5Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 6Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 7Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 8Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:10/22/2014)... Brownsville, TX (PRWEB) October 22, 2014 On ... will present its fourth annual family health and fitness fair ... Hispanic family physical activity and good nutrition for better health ... This event, which is free and open to the public, ... Street, in Brownsville, from 9:00 am to 1:00 pm. ...
(Date:10/22/2014)... October 22, 2014 Isabel Healthcare ... Allied Health Professions (ASAHP) Conference on October 22-24 in ... will participate in a panel discussion on Technology in ... Isabel Healthcare provides a diagnostic decision support tool and ... diagnosis skills of students and clinical learners. The Isabel ...
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
... May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today ... Bay Shore, Long Island. This Center is the Company,s ... new markets that CRH has targeted for,expansion. The opening ... 2008 bringing the Company,s total number of Centers to ...
... lead unhealthy lifestyles are more likely to suffer from ... population-based study of more than 5,000 men and women ... journal BJU International. Researchers hope the results will help ... can be managed more effectively. , According to ...
... Revenue Increased 70.9% to $9.2 Million, CHENGDU, ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of ... today announced fiscal results for its third quarter ... quarter of 2008 increased 70.9% to approximately,$9.2 million ...
... to be Webcast Live at 2:00 p.m. ET Thursday, ... Inc.,(Nasdaq: CYNO ), a leading developer and manufacturer ... announced that its senior,management will present at the 2008 ... the Hilton New York., Cynosure,s presentation will be ...
... MONTVALE, N.J., May 15 Pain is a ... are an important option,for these patients. Physicians must ... the best outcomes for their patients., To ... the proper,opioid analgesic, the dual journals Current Clinical ...
... mouse model hint of new treatment strategies for the disease ... fat, the kind often found in baked and fried goods, ... The finding by University of California, Los Angeles, scientists is ... mouse model that closely mimics human cancer. , The fat ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 3Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 5Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 6Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 7Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 8Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 9Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 10Health News:Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference 2Health News:Treat Your Patients' Pain Effectively 2Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
Medicine Products: